Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Solid Cancer × durvalumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 14 Carcinoma, Non-Small-Cell Lung 9 Pancreatic Neoplasms 7 Ovarian Neoplasms 7 Lung Neoplasms 7 Head and Neck Neoplasms 6 Colorectal Neoplasms 6 Triple Negative Breast Neoplasms 5 Squamous Cell Carcinoma of Head and Neck 5 Urinary Bladder Neoplasms 4 Carcinoma, Hepatocellular 4 Biliary Tract Neoplasms 4 Small Cell Lung Carcinoma 3 Prostatic Neoplasms 3 Neoplasms 3 Neoplasm Metastasis 3 Cholangiocarcinoma 3 Carcinoma, Squamous Cell 3 Carcinoma 3 Uterine Cervical Neoplasms 2 Stomach Neoplasms 2 Non-Muscle Invasive Bladder Neoplasms 2 Lymphoma, T-Cell, Cutaneous 2 Lymphoma, T-Cell 2 Kidney Neoplasms 2 Fallopian Tube Neoplasms 2 Esophageal Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma, Renal Cell 2 Brain Neoplasms 2

Interventions

pembrolizumab 2 atezolizumab 2 trastuzumab deruxtecan 1 toripalimab 1 pertuzumab 1 durvalumab 1 Trastuzumab 1 S-Adenosylmethionine 1 Ramucirumab 1 Paclitaxel 1 Oxaliplatin 1 Nivolumab 1 Leucovorin 1 Irinotecan 1 Fluorouracil 1 Etoposide 1 Cetuximab 1 Carboplatin 1 Capecitabine 1 Bevacizumab 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡